Side Effects

Ozempic Side Effects in Women: What Research Shows About Female-Specific Risks

GLP-1 Companion · 9 min read

Quick answer

While most Ozempic side effects are similar across sexes, women face some unique considerations — including menstrual cycle disruptions, hair loss after rapid weight loss, bone density concerns, and potential interactions with hormonal contraceptives. Here is what the research shows.

Ozempic (semaglutide) was initially approved for type 2 diabetes management, and its weight-loss cousin Wegovy has become one of the most widely prescribed medications for obesity. Clinical trials have included large numbers of women, allowing researchers to identify side effects and considerations that are particularly relevant to female patients. This article focuses on what women specifically need to know — beyond the standard list of GI side effects that apply to everyone.

Common Side Effects: Similar Rates, Potentially Higher Frequency

The most common side effects of Ozempic — nausea, vomiting, diarrhea, constipation, and abdominal pain — occur in both men and women. However, several analyses suggest that women may experience GI side effects at slightly higher rates than men. A 2022 analysis of the SUSTAIN trial data found that female participants had modestly higher rates of nausea and vomiting compared to male participants. This may be related to hormonal differences that influence gastric motility, as estrogen and progesterone are known to slow gastric emptying to varying degrees across the menstrual cycle.

Menstrual Cycle Disruptions

A notable and underreported side effect in women is menstrual cycle irregularity. GLP-1 receptors have been identified in ovarian tissue, and semaglutide's metabolic effects — particularly the significant caloric deficit and rapid weight loss — can disrupt hypothalamic-pituitary-ovarian (HPO) axis signaling.

Irregular periods: Many women report changes to cycle length, timing, or flow, particularly in the first 3–6 months of GLP-1 treatment.
Missed periods: Significant caloric restriction and rapid weight loss can temporarily suppress ovulation, similar to what occurs in female athletes with low energy availability.
Improved cycles in PCOS patients: Paradoxically, women with polycystic ovary syndrome (PCOS) often see cycle regularization on GLP-1 therapy, as insulin resistance — a key PCOS driver — improves.
Heavier periods initially: Some women report temporarily heavier menstrual bleeding at treatment onset, though the mechanism is not well understood.

Fertility and Pregnancy Considerations

Women of reproductive age on GLP-1 medications should be aware of two important fertility-related considerations.

Increased Fertility Risk

Weight loss can restore or enhance ovulation in women who were previously anovulatory due to obesity or PCOS. This means women who previously had difficulty conceiving may become fertile while on GLP-1 therapy — sometimes unexpectedly. It is important to use reliable contraception if pregnancy is not desired.

Reduced Oral Contraceptive Effectiveness

Semaglutide slows gastric emptying, which can theoretically reduce the absorption of oral contraceptive pills (OCPs). Novo Nordisk recommends that women on once-weekly semaglutide switch to non-oral contraception (e.g., implant, IUD, patch, ring) or add a barrier method as a precaution. This interaction has not produced a formally documented case of OCP failure in clinical literature, but the theoretical concern warrants discussion with a healthcare provider.

Not Safe During Pregnancy

Semaglutide is contraindicated during pregnancy. Animal studies have shown fetal harm at doses similar to human therapeutic doses. Women planning pregnancy should stop GLP-1 medications at least 2 months before attempting to conceive. Accidental exposure during early pregnancy should be discussed with an obstetrician immediately.

Hair Loss (Telogen Effluvium)

Hair loss is more frequently reported by women on GLP-1 medications and is a common concern. The technical term is telogen effluvium — a shedding of hair that occurs 2–4 months after a physiological stressor, such as rapid weight loss, caloric restriction, or nutritional deficiency.

In the STEP clinical trials for Wegovy, approximately 3% of participants reported hair loss — a rate nearly three times higher than in the placebo group. The good news: this type of hair loss is typically temporary and self-resolving once weight stabilizes and nutrition is optimized. Ensuring adequate protein intake (at least 1.2–1.5 g/kg/day) and sufficient iron, zinc, and biotin levels is important for minimizing severity.

Bone Density and Fracture Risk

Postmenopausal women already face elevated fracture risk due to estrogen-related bone density loss. Rapid weight loss — from any cause — is associated with accelerated bone mineral density (BMD) reduction, as mechanical loading on bones decreases with lower body weight. Some studies have found that GLP-1 medications may have a neutral or even mildly protective effect on bone turnover markers, but this area remains under active investigation.

Women on GLP-1 therapy who are at elevated osteoporosis risk should discuss bone density monitoring (DEXA scans) with their provider, ensure adequate calcium (1,000–1,200 mg/day) and vitamin D (1,500–2,000 IU/day) intake, and continue or begin resistance training, which is the most potent lifestyle intervention for bone preservation.

Mental Health and Emotional Changes

Some women on GLP-1 medications report mood changes — including both positive effects (reduced anxiety around food, improved self-image) and occasionally negative effects (emotional blunting, increased irritability, or low mood). These changes may relate to the medication's direct neurological effects (GLP-1 receptors are abundant in the brain's reward and emotional centers) or to the psychological adjustment of a rapidly changing body image. Women with a history of mood disorders or eating disorders should discuss these risks with their provider before starting.

Benefits That May Be Particularly Meaningful for Women

PCOS management: Weight loss via GLP-1 medications significantly reduces insulin resistance, a core driver of PCOS, often improving hormonal balance, cycle regularity, and androgen levels.
Reduced cardiovascular risk: The SELECT trial showed a 20% reduction in major adverse cardiovascular events with semaglutide — a benefit that extends to women.
Improved menopausal symptoms: Some women report that weight loss reduces the severity of hot flashes and improves sleep, though direct trial evidence is limited.
Reduced cancer risk: Obesity is a risk factor for several cancers including breast, uterine, and ovarian cancers; weight loss may reduce this risk over time.

The Bottom Line

Ozempic and GLP-1 medications are generally safe and highly effective for women. The key female-specific considerations are: potential menstrual disruption (usually temporary), reduced OCP reliability, absolute contraindication in pregnancy, higher risk of hair loss and emotional changes, and the need for bone health monitoring in at-risk women. All of these can be managed with appropriate medical supervision.